Department of Pathology, Peking University Shenzhen Hospital, Shenzhen, China.
Department of Pathology, Caritas Medical Center, Shamshuipo, Hong Kong.
Lab Invest. 2023 Jul;103(7):100135. doi: 10.1016/j.labinv.2023.100135. Epub 2023 Mar 24.
To characterize the clinicopathologic features of pulmonary sclerosing pneumocytoma (PSP) and compare these features between the tumors with and without metastasis, 68 cases of PSP (1/68 [1.47%] with metastasis) diagnosed from 2009-2022 in our hospital and 15 previously reported metastasizing cases were studied. There were 54 female patients and 14 male patients, with age ranging from 17 to 72 years and tumor size ranging from 0.1 to 5.5 cm (mean, 1.75 cm). In all, 85.4% of the cases presented with ≥2 patterns, including papillary, sclerotic, solid, and hemorrhagic. Thyroid transcription factor 1, epithelial membrane antigen, CKpan, and CK7 were expressed in surface cells in 100% of the cases and napsin A was expressed in 90% of the cases. Stromal cell expression of these markers occurred in 100%, 93.9%, 13.5%, 13.8%, and 0% of the cases, respectively. Of the 16 PSP cases with metastasis, 8 were female patients and 7 were male patients, with age ranging from 14 to 73 years. The tumor size ranged from 2.5 to 12 cm (mean, 4.85 cm). Forty-five of the cases were negative for BRAF V600E immunostaining and 6 were focally weak positive, in which fluorescent PCR tests showed no detectable mutations. There were significant differences in gender, age, and tumor size between PSP cases with and without metastasis. No BRAF V600E mutation was found in patients with PSP. AKT1 p.E17K mutations were detected in both the primary lung tumor and the lymph node metastatic tumor of our PSP case with lymph node metastasis. In conclusion, PSP is an uncommon pulmonary neoplasm with significant female predilection and has distinct morphologic and immunohistochemical characteristics. The BRAFV600E mutation was not detectable in patients with PSP and thus may not involve in its tumorigenesis. Most PSP tumors are benign, with a minority exhibiting potential for metastasis and malignant behavior.
为了描述肺硬化性细支气管肺泡细胞瘤(PSP)的临床病理特征,并比较有和无转移的肿瘤之间的这些特征,研究了我院 2009-2022 年间诊断的 68 例 PSP(1/68[1.47%]有转移)和 15 例先前报道的转移病例。患者中 54 例为女性,14 例为男性,年龄 17-72 岁,肿瘤大小 0.1-5.5cm(平均 1.75cm)。所有病例中有 85.4%表现出≥2 种形态,包括乳头、硬化、实性和出血性。甲状腺转录因子 1、上皮膜抗原、CKpan 和 CK7 在所有病例的表面细胞中均表达 100%,napsin A 在 90%的病例中表达。间质细胞对这些标志物的表达分别为 100%、93.9%、13.5%、13.8%和 0%。16 例有转移的 PSP 病例中,女性 8 例,男性 7 例,年龄 14-73 岁。肿瘤大小 2.5-12cm(平均 4.85cm)。45 例 PSP 病例 BRAF V600E 免疫染色阴性,6 例弱阳性,荧光 PCR 检测未检出可检测的突变。有转移和无转移的 PSP 病例在性别、年龄和肿瘤大小方面存在显著差异。在 PSP 患者中未发现 BRAF V600E 突变。在我们的 PSP 病例中,淋巴结转移的原发性肺肿瘤和淋巴结转移性肿瘤均检测到 AKT1 p.E17K 突变。总之,PSP 是一种罕见的肺部肿瘤,具有明显的女性倾向,具有独特的形态和免疫组织化学特征。在 PSP 患者中未检测到 BRAFV600E 突变,因此其肿瘤发生可能不涉及 BRAF 基因突变。大多数 PSP 肿瘤为良性,少数具有转移和恶性行为的潜能。